Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.

Video: Tengion Neo-Urinary Conduit™

Watch as the neo-urinary conduit development process is described for use in patients with bladder cancer.

* IE users only: You may be redirected to upgrade
security components and install an Active X control.

The video you are linking to depicts experimental technology invented by, and procedures performed at, Children's Hospital Boston. This technology serves as the foundation for Tengion's lead product candidate, the Neo-Bladder Augment, which is currently in Phase 2 clinical trials. Tengion's Neo-Bladder Augment is investigational and has not been approved by the FDA for commercial sale. Additionally, the Neo-Bladder Augment may not be appropriate for all patients and medical results depicted in this video may not be experienced by others using this technology.

Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina January 5, 2012

Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting December 13, 2011

Tengion Appoints John L. Miclot President and Chief Executive Officer December 5, 2011

Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference November 21, 2011

Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results November 14, 2011

Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.

All News »